Insight Molecular Diagnostics Inc. Common Stock logo

Insight Molecular Diagnostics Inc. Common Stock (IMDX) Q1 2026 Earnings

IMDX·Reported May 13, 2026·After market close

Insight Molecular Diagnostics Inc. Common Stock reported Q1 2026 revenue of $32.0K (-98.5% YoY), missed analyst consensus of $229.2K by $197.2K. Diluted EPS came in at $-0.28 (-7.7% YoY), missed the $-0.26 consensus by $0.02.

Revenue
$32.0Kmissed by $197.2K
Consensus: $229.2K
Diluted EPS
$-0.28missed by $0.02
Consensus: $-0.26
SEC

SEC Filings

Earnings release8-K/A · 0001493152-26-022708
Quarterly report10-Q · 0001642380-26-000008

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Insight Molecular Diagnostics Inc. Common Stock's Q1 2026 earnings report.

Insight Molecular Diagnostics Inc. Common Stock (IMDX) reported Q1 2026 earnings on May 13, 2026 after market close.

Insight Molecular Diagnostics Inc. Common Stock reported revenue of $32.0K and diluted EPS of $-0.28 for Q1 2026.

Revenue missed the consensus estimate of $229.2K by $197.2K. EPS missed the consensus estimate of $-0.26 by $0.02.

Compared to the same quarter a year prior, revenue declined 98.5% from $2.1M a year earlier and diluted EPS declined 7.7% from $-0.26.

You can read the 8-K/A earnings release (0001493152-26-022708) and the 10-Q periodic report (0001642380-26-000008) directly on SEC EDGAR. The filing index links above go to sec.gov.